Sanj K. Patel Sells 2,872 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CEO Sanj K. Patel sold 2,872 shares of the company’s stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $27.03, for a total value of $77,630.16. Following the transaction, the chief executive officer now directly owns 96,674 shares in the company, valued at $2,613,098.22. The trade was a 2.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Kiniksa Pharmaceuticals Price Performance

Shares of KNSA stock opened at $26.25 on Friday. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $17.38 and a fifty-two week high of $28.56. The stock’s 50-day moving average is $22.86 and its two-hundred day moving average is $21.35. The firm has a market cap of $1.92 billion, a P/E ratio of -187.49 and a beta of 0.07.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.09. The company had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business’s revenue was up 72.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.25) EPS. As a group, research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on KNSA. Citigroup began coverage on Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They issued a “buy” rating and a $40.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Finally, Jefferies Financial Group upped their target price on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, April 29th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $38.80.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in KNSA. Nuveen LLC acquired a new position in shares of Kiniksa Pharmaceuticals during the 1st quarter valued at about $16,992,000. Braidwell LP increased its holdings in shares of Kiniksa Pharmaceuticals by 19.3% during the 4th quarter. Braidwell LP now owns 3,452,447 shares of the company’s stock valued at $68,289,000 after acquiring an additional 557,934 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Kiniksa Pharmaceuticals by 149.1% during the 1st quarter. AQR Capital Management LLC now owns 491,761 shares of the company’s stock valued at $10,922,000 after acquiring an additional 294,319 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Kiniksa Pharmaceuticals by 138.9% during the 4th quarter. JPMorgan Chase & Co. now owns 477,800 shares of the company’s stock valued at $9,451,000 after acquiring an additional 277,827 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Kiniksa Pharmaceuticals by 50.9% during the 4th quarter. Millennium Management LLC now owns 779,672 shares of the company’s stock valued at $15,422,000 after acquiring an additional 263,146 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.